Quantcast

Cambridge Semantics Integrates ChemAxon Search and Visualization Capabilities into Anzo Software

February 18, 2014

Pharma, biotech firms now able to combine different chemical search methodologies.

Cambridge, Mass. (PRWEB) February 18, 2014

Cambridge Semantics, the leading provider of Unified Information Access (UIA) solutions for enterprises, today announced it has partnered with ChemAxon to provide customers with advanced chemical search and visualization capabilities.

ChemAxon’s products and services focus on adding functionality and value to chemistry information and provides cheminformatics software platforms, applications and services to optimize the value of chemistry information in life science and other R&D. Based on semantic technology, Cambridge Semantics’ Anzo software addresses a variety of enterprise data management and end-user data consumption challenges in the pharma, financial and life science industries.

With the integration, Anzo customers gain the ability to perform chemical structure searches over their existing databases that contain chemical data by directly drawing substructures as well as the ability to visualize chemical structures within their Anzo Web dashboards.

ChemAxon customers can now easily integrate other sources of data with their chemical structure data while also being able to quickly setup searchable knowledge bases and dashboards of chemical data combined with any other related data with Anzo’s easy-to-use tools.

“With ChemAxon integrated into Anzo software, pharma companies can more easily find all of the papers related to a particular chemical substructure in patent information, publications and other drug research databases,” said Lee Feigenbaum, co-founder and vice president of marketing and technology for Cambridge Semantics. “Another example is a customer could better locate biotech companies developing an asthma drug in phase 1 or 2 of development that has an active compound matching a particular chemical substructure.”

“The combined power of our robust chemistry search and visualization capabilities with Anzo’s ability to find highly useful information quickly will be a huge benefit to global pharma companies as well as major chemical and agrochemistry companies, biotech enterprises and academic research centers,” said Alex Drijver, CEO of ChemAxon. “We are delighted to have Cambridge Semantics join our wide array of partners who chose our platform as the chemical search engine of choice when adding chemical intelligence to their applications."

About ChemAxon

ChemAxon is a leader in providing cheminformatics software platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions that power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest, US East Coast headquarters in Cambridge, MA, and sales and support offices in Europe, Japan and across North America.

About Cambridge Semantics

Cambridge Semantics provides the award-winning Anzo software suite, an open platform for building interactive Unified Information Access (UIA) solutions. Enterprises face an increasing need to rapidly discover, understand, combine, and act on data from diverse sources both from within and across organizational boundaries. Anzo makes it easy for both IT and end users to deal with this need by rapidly creating solutions that leverage unified access to structured and unstructured data from varied sources in the context of specific business problems.

Cambridge Semantics is privately held and based in Boston, Massachusetts. For more information visit http://www.cambridgesemantics.com or follow us on Twitter @CamSemantics.

For the original version on PRWeb visit: http://www.prweb.com/releases/2014/02/prweb11592230.htm


Source: prweb



comments powered by Disqus